There are currently 2700 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion
NCT06855771
Recruiting
The purpose of this study is to evaluate the safety and efficacy of BMS-986504 monotherapy in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion after progression on prior therapies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Local Institution - 0090, Boston, Massachusetts
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
CUE-102 in Recurrent Glioblastoma
NCT06917885
Recruiting
The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM). The name of the study drug involved in this study is: -CUE-102 (a type of fusion protein)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Recurrent Glioblastoma, Glioblastoma, Glioma, Malignant
Register for Updates
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT06928142
Recruiting
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/07/2025
Locations: Tufts University School of Dental Medicine, Boston, Massachusetts
Conditions: Sjogren Disease
Register for Updates
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT02332668
Recruiting
Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is... Read More
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
07/04/2025
Locations: Call for Information (Investigational Site 0026), Boston, Massachusetts
Conditions: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Register for Updates
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT05081609
Recruiting
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile enabled by the TransCon technology, TransCon IL-2 β/γ presents the opportunity to enhance the therapeutic index of current IL-2 thera... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2025
Locations: Ascendis Pharma Investigational Site, Boston, Massachusetts
Conditions: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Register for Updates
A Global Study of the PETAL Consortium
NCT06067347
Recruiting
The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: T-Cell and NK-Cell Neoplasm
Register for Updates
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128
Recruiting
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2025
Locations: ~Mass General Hospital- Site Number : 8400009, Boston, Massachusetts
Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Register for Updates
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
NCT06042257
Recruiting
The purpose of this study is to determine efficacy of guanfacine immediate release (GIR) for the treatment of hyperactivity/impulsivity and inattention in children 6-12 years of age with Down syndrome (DS) after 8 weeks of treatment.
Gender:
ALL
Ages:
Between 6 years and 12 years
Trial Updated:
07/03/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome
Register for Updates
Chiropractic Care for Episodic Migraine
NCT06229834
Recruiting
Migraine, a chronic intermittent headache disorder, ranks in the top five causes of years lived with disability. One promising non-pharmacologic and integrative treatment for migraine may be chiropractic care due to the co-occurrence of migraine and musculoskeletal complaints. The goal of this application is to perform a pilot study of chiropractic care for episodic migraine to help inform the design of a future, full-scale pragmatic effectiveness trial.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/03/2025
Locations: Osher Center for Integrative Health, Mass General Brigham, Boston, Massachusetts
Conditions: Episodic Migraine
Register for Updates
Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
NCT06399302
Recruiting
This project aims to collect detailed clinical data, blood samples, and patient-reported outcomes from 2,600 lung transplant candidates, donors, and recipients at Lung Transplant Centers. The goal is to create a robust resource for various research objectives, including studying the impact of variations in donor and medical practices on clinical outcomes. The project also seeks to identify serum biomarkers associated with or predictive of specific post-transplant complications and conditions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2025
Locations: Brigham and Womens Hospital, Boston, Massachusetts
Conditions: Lung Transplant; Complications, Lung Transplant; Infection or Inflammation, Lung Transplant Rejection, Lung Transplant Failure
Register for Updates
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934
Recruiting
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 years and older diagnosed with moderate-to-severe atopic dermatitis (AD). The main objective of this study is to evaluate if those participants who received amlitelimab dose 1 in the parent studies (EFC17559 \[COAST-1\], EFC17560 \[COAST 2\], EFC17561 \[SHORE\]) and were responders can maintain their response either remaining at dose 1 or switching to... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/03/2025
Locations: Beth Israel Deaconess Medical Center - Fort Myers- Site Number : 8401286, Boston, Massachusetts
Conditions: Dermatitis Atopic
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients
NCT06706674
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
07/03/2025
Locations: Clinical Site, Boston, Massachusetts
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates